Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,

Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,

#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3

Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Friend E, Gray D, Fernández Ortega P, McNamara M, Kaltsas G,

Keywords: research, neuroendocrine, insulinoma, gastrinoma, non-functioning, VIPoma, Glucagonoma, questionnaire, quality of life,

#2947 Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients

Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K,

Keywords: neuroendocrine tumors, PET, Al18F-NOTA-octreotide, 68Ga-DOTATATE, somatostatin receptor imaging,

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,

#2935 Prior Surgical Resection and Ga-68-DOTANOC PET/CT Imaging-Based Parameters: Do These Impact Outcomes in Grade II Gastroentero-Pancreatic Neuroendocrine Tumors (GEP-NETs)

Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Puranik A

Authors: Puranik A, Agrawal A, Rangarajan V, Shrikhande S, Dev I,

Keywords: Grade 2, GEP-NET, DOTANOC, surgical resection,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.